Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06351332 · ClinicalTrials.gov registry record · Phase 1

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

A Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Filipa Lynce, MD.

Active
Registry status
Phase 1
Development phase
78
Enrollment target
1
Study location

NCT06351332 is a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Filipa Lynce, MD. The registered enrollment target is 78 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06351332, a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Filipa Lynce, MD.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a type of WEE1 inhibitor) * Carboplatin (a type of platinum compound) * Pembrolizumab (a type of monoclonal antibody)

Conditions Studied

Breast Cancer Triple Negative Breast Cancer HER2-Negative Breast Cancer Breast Cancer Female Hormone Receptor Negative Malignant Tumor Breast Triple

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Azenosertib

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2024-05-01
Est. Completion 2029-09-01
Phase Phase 1

Sponsor

Filipa Lynce, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06351332

The ClinicalTrials.gov registry entry for NCT06351332 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Filipa Lynce, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT06351332 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06351332 about?

NCT06351332 is a clinical study titled "ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC". This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a t...

What is the current status of trial NCT06351332?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-05-01. Estimated completion is 2029-09-01.

What conditions does trial NCT06351332 study?

This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, HER2-Negative Breast Cancer, Breast Cancer Female, Hormone Receptor Negative Malignant Tumor Breast Triple.

What interventions are being tested in trial NCT06351332?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Azenosertib (DRUG).

Who is sponsoring clinical trial NCT06351332?

This trial is sponsored by Filipa Lynce, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06351332 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Triple Negative Breast Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.